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Receptor-interacting protein 1 (RIP1) is a Ser/Thr kinase with both kinase-dependent and kinase-independent roles in death
receptor signaling. The kinase activity of RIP1 is required for necroptosis, a caspase-independent pathway of programmed cell
death. In some cell types, the inhibition of caspases leads to autocrine production of TNFa, which then activates necroptosis.
Here, we describe a novel role for RIP1 kinase in regulating TNFa production after caspase inhibition. Caspase inhibitors
activateRIP1kinaseandanotherprotein,EDD,tomediateJNKsignaling,whichstimulatesSp1-dependenttranscriptionofTNFa.
This pathway is independent of nuclear factor jB and also occurs after Smac mimetic/IAP antagonist treatment or the loss of
TNF receptor-associated factor 2 (Traf2). These ﬁndings implicate cIAP1/2 and Traf2 as negative regulators of this RIP1 kinase-
dependent TNFa production pathway and suggest a novel role for RIP1 kinase in mediating TNFa production under certain
conditions.
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Receptor-interacting protein 1 (RIP1) is a multi-functional signal
transducer involved in mediating nuclear factor kB( N F - kB)
activation, apoptosis, and necroptosis. The kinase activity of
RIP1 is critically involved in mediating necroptosis, a caspase-
independent pathway of necrotic cell death.
1,2 RIP1 kinase and
necroptosis are activated by death receptor ligands, such as
TNFa and Fas, when apoptosis is blocked.
1,3 Necrostatin-1
(Nec-1), a small molecule inhibitor of RIP1 kinase activity, can
also block necroptosis. In some cell types, such as mouse
ﬁbrosarcoma L929 cells, necroptosis is activated by inhibition
of caspase activity using a pan-caspase inhibitor such as
zVAD.fmk.
3 How RIP1 kinase is activated to mediate necrop-
tosis induced by caspase inhibition is not clear.
RIP1 is ubiquitinated by the cellular inhibitor of apoptosis
proteins, cIAP1 and cIAP2.
4,5 RIP1 is ubiquitinated by a
number of other E3 ubiquitin ligases as well, suggesting that
RIP1 ubiquitination might regulate RIP1 activity. Smac
mimetics (SMs) are a class of compounds modeled after the
N terminus of a cellular protein, Smac/DIABLO, that inhibits
the IAPs. SMs are under development as anti-cancer drugs.
6,7
In some cell types, SM treatment can induce autocrine TNFa
production and cell death, although the pathway has not been
fully elucidated.
7–10
TNFa is an important pro-inﬂammatory cytokine involved in
mediating cell death and inﬂammation in many human
diseases such as rheumatoid arthritis and cancers. In a
genome-wide siRNA screen to identify genes involved in
necroptosis, we found that knockdown of tnfr1 or treatment
with a TNFa-neutralizing antibody was protective against
zVAD.fmk-induced cell death in L929 cells, indicating that
zVAD.fmk was likely inducing autocrine TNFa production.
11
As knockdown of RIP1 protects against zVAD.fmk-induced
death,
11 we tested the hypothesis that RIP1 might act
upstream of TNFa production after zVAD.fmk and identiﬁed
a novel function of RIP1 kinase in mediating TNFa production.
EDD/UBR5/hHYD is a putative tumor suppressor and
HECT (homologous to E6-AP C-terminus)-domain-containing
E3 ubiquitin ligase implicated in cellular pathways including
the regulation of gene expression, the DNA damage
response, and in necroptosis after it was identiﬁed in a siRNA
screen.
11,12 EDD regulates gene expression transcriptionally,
by forming complexes with transcription factors, and transla-
tionally by regulating protein levels of Paip2, a poly-A-binding
protein inhibitor.
13,14 EDDisalso importantin thecellular DNA
damage response, mediating ATM phosphorylation of its
substrates CHK2 and p53 after DNA damage to control cell
cycle arrest.
15–17 Given its multiple functions in mediating
cellular processes, EDD likely acts as a chaperone protein,
coordinating the various protein complexes involved in
different cellular pathways.
In this study, we describe a novel RIP1 kinase-dependent
TNFa production pathway occurring in cellular models of
necroptosis and apoptosis. We explored this novel TNFa
productionpathwayusingacombinationofchemicalinhibitors
and genetic analysis, and deﬁned a protein complex contain-
ing EDD, RIP1, and cIAP1 that mediates JNK activation and
transcription of TNFa.This TNFaproduction pathway requires
RIP1 kinase and is activated speciﬁcally in response to
zVAD.fmk stimulation, SM compounds, or TNF receptor-
associated factor 2 (Traf2) deﬁciency.
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RIP1 and EDD are required for TNFa production in
response to zVAD.fmk. To directly examine whether
zVAD.fmk stimulates the production of TNFa, we measured
TNFa levels after zVAD.fmk treatment. TNFa could be
detected in dying L929 cells treated with zVAD.fmk. Nec-1,
a RIP1 kinase inhibitor, blocked the increase in TNFa protein
levels as well as cell death (Figures 1a and b).
Astheknockdown ofRIP1canhave differential effectsfrom
the inhibition of its kinase activity alone,
11 we used Nec-1 as a
tool to examine the role of RIP1 kinase in TNFa production.
Although Nec-1 has been shown to be a speciﬁc inhibitor of
RIP1 kinase,
2 we further tested the speciﬁcity of Nec-1 to
ensure its suitability for this study. Nec-1 speciﬁcally binds
RIP1 with Kd 5.6nM for racemic Nec-1 and Kd 3.1nM for
R-Nec-1 (Supplementary Figure S1a). Using KINOMEscan
(Ambit Biosciences, San Diego, CA, USA),
18 Nec-1 (10mM)
was tested for activity against 485 kinases and activated
mutant kinases. When ranked in order of inhibition, RIP1 is
the top kinase inhibited by Nec-1 (Supplementary Figure
S1b). Aside from RIP1, no kinases were inhibited greater than
60% by Nec-1. PDGFRb was inhibited by 72%, however, the
Kd of binding of Nec-1 to PDGFRb was greater than 30mM,
suggesting a false positive (Supplementary Figures S1a and
b). Nec-1 is more speciﬁc than 35 known kinase inhibitors
including imatinib (Gleevec) (Supplementary Figure S1c). As
further evidence, Nec-1 can only protect against necroptosis
in Rip1þ/þ MEF cells, but not in Rip1 /  MEFs
(Supplementary Figure S1d). Thus, we conclude that Nec-1
is a highly speciﬁc inhibitor of RIP1 kinase activity and an
appropriate tool with which to study the speciﬁc role of RIP1
kinase.
L929 cells are exquisitely sensitive to death induced
by TNFa treatment, so to directly study the effect of RIP1 on
TNFa production we tested different cell types that produce
TNFa in response to zVAD.fmk treatment. A mouse macro-
phagecellline,J774,wasfoundtoproduceeasilymeasurable
TNFa levels in response to zVAD.fmk stimulation (Figure 1c).
Both primary macrophages and macrophage cell lines
undergo necroptosis in response to zVAD.fmk.
11,19 Although
J774 cell treatment with zVAD.fmk induced necroptosis, cell
death was not dependent on the production of TNFa. Cell
death was observed beginning at least 12h after the increase
in TNFa was ﬁrst detected and neutralization of TNFa was not
sufﬁcient to block zVAD.fmk-induced necroptosis of J774
cells (Figure 1b). Inhibition of RIP1 kinase by Nec-1
completely blocked the production of TNFa in J774 cells,
suggestingthatRIP1kinaseisrequiredforTNFaproductionin
zVAD.fmk-treated J774 cells (Figure 1c).
The production of TNFa in response to zVAD.fmk treatment
was blocked by CHX suggesting that de novo protein
synthesis is involved (Figure 1d). Consistent with this
possibility, our siRNA screen found a signiﬁcant enrichment
of transcription factors and nucleic acid-binding genes among
hits protecting against zVAD.fmk-induced necroptosis.
11
Treatment with zVAD.fmk activates de novo synthesis of
TNFa though a mechanism dependent upon the kinase
activity of RIP1.
To ﬁnd additional components of the RIP1 kinase-depen-
dent pathway of TNFa production, we identiﬁed RIP1-binding
proteins. 293T cells were transfected with a vector expressing
Flag-tagged RIP1 kinase, and RIP1 immunocomplexes were
isolated using anti-Flag. The binding proteins were identiﬁed
by mass spectrometry analysis. This analysis identiﬁed
FADD, a known RIP1-binding protein, thus validating the
Figure 1 RIP1 kinase activatesTNFa production. (a) TNFa levels determinedby TNFa ELISA andnormalizedto totalprotein in lysatefrom L929 cellstreatedwith 20mM
zVAD.fmk ±10mM Nec-1 for 16h. (b) L929 or J774 cells treated with 20mM zVAD.fmk±1.0mg/ml anti-mTNFa or 10mM Nec-1. Cell viability measured by ATP assay after
24h. (c) TNFa levels in J774 cells treated with 20mM zVAD.fmk±10mM Nec-1 for 4 and 8h were determined as in a.( d) TNFa levels in J774 cells treated with 20mM
zVAD.fmk±0.5mg/ml CHX. *Po0.05, data shown are mean±S.E.M., n¼3
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Cell Death and Diseaseexperiment. To distinguish binding proteins that have a
functional role in mediating the production of TNFa,w e
compared the list of mass spectrometry-identiﬁed proteins
with the hits identiﬁed in the genome-wide siRNA screen for
genes involved in mediating necroptosis of L929 cells in
response to zVAD.fmk.
11 EDD, encoded by the gene edd1,i s
both a RIP1-binding protein and a gene whose knockdown
blocks zVAD.fmk-induced necroptosis. We conﬁrmed that
RIP1 coimmunoprecipitated EDD (Figure 2a). Interestingly,
overexpression of EDD consistently increases the levels of
exogenously expressed RIP1 protein but has no effect on
endogenous RIP1, suggesting that overexpressed RIP1 is
stabilized by EDD (Figure 2a, Supplementary Figure S2a).
Knockdown of EDD protected against zVAD.fmk but not
TNFa-induced necroptosis (Figure 2b), indicating EDD does
not have any role in TNFa-induced necroptosis and instead
has a likely role in zVAD.fmk-induced TNFa production. To
determine whether EDD is required for TNFa production, we
generated stable knockdown cell lines using retroviral infec-
tion of an shRNA construct against EDD. Knockdown of EDD
inhibitedzVAD.fmk-induced TNFa,demonstrating thatEDDis
required for TNFa production (Figure 2c).
To determine how TNFa production is activated, we used
real-timePCR tomeasure TNFa mRNA levels after zVAD.fmk
treatment. Stimulation with zVAD.fmk increased TNFa
mRNA, and treatment with Nec-1, or knockdown of EDD,
was able to block the increase in TNFa mRNA (Figure 2d).
Thus, RIP1 and EDD activate the transcription of TNFa after
zVAD.fmk treatment.
SM induces TNFa in a manner dependent on RIP1 kinase
and EDD. To explore the physiological relevance of this
pathway, we looked for other stimuli that could also activate
this RIP1 kinase-dependent pathway of TNFa production. SM
induces autocrine TNFa production in some cells.
7–10 Thus,
we tested whether RIP1 and EDD have role in SM-induced
TNFa. Treatment with SM induces the auto-ubiquitination and
degradation of cIAP1 and cIAP2, and also blocks XIAP
binding to and inhibition of caspases. We tested the effect of
the previously described SM-164
20,21 on L929 cells and found
that, similar to zVAD.fmk, SM-164 induced TNFa-dependent
necrotic cell death that could be inhibited by Nec-1 or a TNFa-
neutralizing antibody (Figure 3a). Knockdown of RIP1, EDD,
or TNFR1 was able to block SM-induced necroptosis, sug-
gesting that SM might be activating the same RIP1- and
EDD-dependent pathway of TNFa production as zVAD.fmk
(Figure 3b). ELISA was used to detect an increase in TNFa
i nt h el y s a t eo fS M - t r e a t e dL 9 2 9c e l l s .S M - i n d u c e dT N F a
could be inhibited by Nec-1 treatment and in EDD-knockdown
cells, conﬁrming that SM activates RIP1 kinase and
EDD-dependent TNFa production (Figure 3c).
Traf2, an E3 ubiquitin ligase, is constitutively bound to
cIAP1/2 within the cell.
22,23 Traf2-knockout mice have
elevated levels of serum TNFa,
24 which suggested to us that
Traf2 might act similarly to cIAP1/2 to inhibit induction of
TNFa. Indeed, knockdown of Traf2 in L929 cells induced
TNFa-dependent necroptosis that could be blocked by both
TNFa-neutralizing antibody or knockdown of TNFR1
(Figure 3d). Similar to SM- and zVAD.fmk-induced cell death,
Traf2 knockdown-induced death could be blocked by Nec-1
and by knockdown of RIP1 or EDD (Figure 3d). Thus, the
absence of Traf2, similar to the loss of cIAP1/2 during SM
treatment, activates RIP1- and EDD-dependent TNFa
production.
Figure 2 EDD mediates TNFa production. (a) 293T cells transfected with Flag-EDD and Flag-RIP1 as indicated. Cell lysates and anti-EDD immunoprecipitates were
western blotted with anti-RIP1 and anti-EDD to show both endogenousand overexpressed protein. (b) L929 cells transfected for 48h with siRNA targetingRIP1 or one of the
fourdifferentsiRNAs targetingEDD were treatedfor 24h with 20mM zVAD.fmk or 10ng/ml hTNFa and cell viability was measured by ATP assay (top)or lysatescollected for
western blot (bottom) to checkprotein knockdown. (c) J774 cells (left) or L929 cells (right) stably expressing shRNA against EDD or an empty vector control were treatedwith
20mMzVAD.fmkandTNFameasuredasina.EDDknockdownshowninFigure6eandSupplementaryFigureS3a.(d)Real-timePCRofRNAisolatedfromJ774cellstreated
with zVAD.fmk with or without Nec-1 (left) or EDD stable knockdown J774 cells treated with zVAD.fmk (right). Relative levels of TNFa transcript were determined compared
with GAPDH (left) or 18S rRNA (right) and the fold change was calculated by comparing with DMSO-treated cells. *Po0.05, data shown are mean±S.E.M., for all
experiments n¼3
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Cell Death and DiseaseSM-induced TNFa production has been studied in
human cancer cell lines including breast, ovarian, and lung
cancer cells. To validate the role of this RIP1- and
EDD-dependent pathway in a previously established model
of autocrine TNFa production, we tested the effect of Nec-1
and EDD knockdown on SM-induced apoptosis in the human
breast cancer MDA-MB-231 cells. MDA-MB-231 cells
undergo TNFa-dependent apoptosis with 100nM SM-164.
20
As has been previously shown, knockdown of RIP1 is able to
block SM-induced apoptosis (Figure 4a).
7 However, neither
Nec-1 treatment nor knockdown of EDD inhibited 100nM SM-
induced apoptosis (Figures 4a and b). Surprisingly, we found
that a 1000-fold lower dose of SM-164 (0.1nM) is sufﬁcient
to induce TNFa-dependent apoptosis, with death blocked
by a TNFa-neutralizing antibody or by caspase inhibition. This
‘low dose’ of SM induces RIP1 kinase-dependent cell
death that is blocked by Nec-1 or by knockdown of EDD
(Figure 4c).
Todetermine whether RIP1 kinaseinduces TNFa transcrip-
tion in the MDA-MB-231 cell model, we measured TNFa mRNA
levels by real-time PCR after treatment with either 0.1nM or
100nM SM-164. Both doses of SM increased TNFa transcrip-
tion, but Nec-1 was only able to inhibit TNFa transcription in
the cells stimulated with the low dose of SM (Figure 4d). The
high, 100nM dose of SM might be activating additional or non-
speciﬁc pathways that contribute to TNFa transcription and
cell death in a RIP1 kinase-independent manner. Low-dose
SMactivatesaspeciﬁcRIP1kinase-dependentmechanismof
TNFa transcription.
A complex of EDD, RIP1, and the E3 ligase cIAP1
regulates TNFa production. To conﬁrm the complex of
Figure 3 Traf2 and cIAP1 inhibit RIP1- and EDD-dependent TNFa production. (a) ATP assay of L929 cells treated with 100nM SM-164±TNFa-neutralizing antibody or
10mM Nec-1 for 24h. (b) Viability of L929 cells transfected with siRNA against RIP1, EDD, TNFR1, or negative control (NC) for 48h and treated with 20mM zVAD.fmk or
100nM SM-164 for 24h. (c) TNFa levels were measured by ELISA in L929 cells treated with 100nM SM-164±10mM Nec-1 (left) or stably expressing EDD shRNA or vector
control (pSRP) and treated with 100nM SM-164 (right). (d) ATP assay of L929 cells transfected with siRNA against Traf2 and treated for 72h, with 1.0mg/ml anti-mTNFa
antibody or 10mM Nec-1 (left). For western blot, the cells were treated with 10mM Nec-1 from the start of transfection to block cell death and harvested after 48h. L929 cells
transfected with siRNAs targeting Traf2 and either RIP1, EDD, or TNFR1. NC±siRNA treated with zVAD.fmk used as positive control. Viability was calculated as the ratio of
the luminescence values of Traf2þsiRNA to untreated NCþsiRNA (right). *Po0.05, data shown are mean±S.E.M., for all experiments n¼3
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Cell Death and DiseaseEDD with RIP1, we examined the interaction of EDD and
RIP1. We found that RIP1 coimmunoprecipitates with
endogenous EDD in a constitutive manner and this binding
is unaffected by RIP1 kinase activation with zVAD.fmk
stimulation (Figure 5a) or after SM treatment (Figure 5b).
Additionally, cIAP1, the target of SM, also coimmunopreci-
pitates with EDD unaffected by zVAD.fmk treatment
(Figure 5c).
To understand the interactions between the proteins in this
complex, we determined the binding domains of RIP1 and
cIAP1 to EDD. We tested the ability of EDD to bind RIP1
truncation mutants lacking the kinase domain (DKD), the
death domain (DDD), and both the intermediate and death
domains (DC). Each of these RIP1 truncation mutants
expressed similarly, except for RIP1 DKD, which expressed
asseveralbands.Thisisnotduetolossofitskinaseactivityas
the kinase inactive RIP1 K45M does not show this expression
pattern (Supplementary Figure S2b). Each of the RIP1
truncation constructs was able to coimmunoprecipitate with
EDD, however, the amount of DKD in the immunocomplex
was enriched compared with that of DCo rDDD, suggesting
that EDD predominantly interacts with the non-kinase domain
of RIP1 (Figure 5d).
EDDwasexpressedwithcIAP1orarelatedfamilymember,
XIAP, to conﬁrm the speciﬁcity of binding. Antibodies against
EDD coimmunoprecipitated cIAP1, but not XIAP (Figure 5e).
Testing the binding of cIAP1 deletion constructs indicated that
BIR1 and BIR2 of cIAP1 are the minimal regions to
coimmunoprecipitate with EDD, and are pulled down with
the same efﬁciency as full-length cIAP1, suggesting that
BIR1-BIR2 is sufﬁcient for cIAP1 to bind EDD (Figure 5f).
There was no binding observed of the BIR3, CARD, or RING-
containing constructs with EDD, indicating these domains do
notinteractwithEDD.TheBIRdomainsofcIAP1alsomediate
its interactions with other proteins such as Traf2, Smac, and
RIP1.
25,26 EDD may act as a scaffold and bind to both cIAP1
and RIP1 kinase. This complex is important for regulating
downstreamsignaling andtheactivationofTNFatranscription
after zVAD.fmk or SM treatment.
A NF-jB independent mode of TNFa production. Both
the canonical and non-canonical NF-kB pathways (NF-kB1
and NF-kB2, respectively) are activated by SM treatment;
inhibition of NF-kB1 blocks TNFa production and cell
death.
9,10 Loss of either cIAP1/2 or Traf2 stabilizes NIK,
inducing the proteasomal processing and activation of
NF-kB2.
9,10,27 Indeed, NF-kB2 is processed and activated
within hours of SM-164 treatment in both 100nM SM-164-
treated MDA-MB-231 cells and SM-treated L929 cells
(Supplementary Figure S2c, Figure 6a). Low-dose SM
(0.1nM) induced NF-kB2 processing in MDA-MB-231 cells
as well, albeit with slower kinetics, likely due to the slower
rate of cIAP1 degradation (Supplementary Figure S2c).
Importantly, Nec-1 had no effect on NF-kB2 processing in
Figure 4 Smac mimetic induces RIP1 kinase- and EDD-dependent TNFa production in MDA-MB-231 cells. (a) ATP assay of MDA-MB-231 cells transfected with NC,
RIP1,orEDDsiRNAfor48handtreatedwith100nMSM-164for24h.(b)TimecourseofMDA-MB-231cellstreatedwith100nMSM-164±20mMzVAD.fmkor10mMNec-1.
Cell viability was measured by ATP assay. (c) ATP assay of MDA-MB-231 cells treated with 0.1nM SM-164±20mM zVAD.fmk, anti-hTNFa-neutralizing antibody, 10mg/ml
CHX, or 10mM Nec-1 for 24h (left). MDA-MB-231 cells transfected with the indicated siRNA for 48h and treated with 0.1nM SM-164 for 24h or harvested for western blot
(right).(d) RT-PCRof RNAfromMDA-MB-231 cellstreatedwith 0.1nM SM-164(top)or100nM SM-164(bottom)±10mM Nec-1for 2,4, or 8h as indicated.Relativelevels of
TNFa transcript determined by normalizing to 18S rRNA transcript and fold change calculated in comparison with DMSO-treated cells. *Po0.05, data shown are
mean±S.E.M., for all experiments n¼3, western blots were repeated two times with similar results
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Cell Death and Diseaseeither low-dose SM-treated MDA-MB-231 cells or SM-
stimulated L929 cells, indicating that RIP1 kinase does not
mediate NF-kB2 activation (Figure 6a, Supplementary Figure
S2c). We were unable to detect the degradation of the
inhibitor protein IkBa, a marker for NF-kB1 activation, under
any stimulation (Figure 6a, Supplementary Figures S2c and
d). As NF-kB is not activated in a RIP1 kinase-dependent
manner after either zVAD.fmk or SM stimulation, NF-kBi s
unlikely to have a role in cell death or TNFa production as
induced by zVAD.fmk or SM in L929 and J774 cells.
Although we did not observe RIP1 kinase-dependent
activation of NF-kB, to verify that NF-kB does not have a
roleinzVAD.fmk-orSM-inducedcelldeath,weknockeddown
NF-kB1 and NF-kB2 and tested the effect on cell death.
Consistent with previously published work,
28 knockdown of
NF-kB1 and NF-kB2 were not protective against necroptosis
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Figure 5 Complex of EDD, RIP1, and cIAP1 activate TNFa production. (a) J774 cells treated with 20mM zVAD.fmk ±10mM Nec-1 and immunoprecipitated with
anti-EDDoranisotype-matchedcontrolantibody(C).Theimmunoprecipitatedproteinswerewesternblottedwithanti-RIP1(representativeofthreeindependentexperiments).
(b) L929 cells were treated with 100nM SM-164 and EDD immunoprecipitated from cells and western blotted for RIP1. (c) L929 cells treated with 20mM zVAD.fmk or 100nM
SM-164 for 7h and EDD immunoprecipitated and western blotted for cIAP1 interaction. (d) EDD immunoprecipitated from 293T cells expressing EDD and the indicated
Flag-RIP1 construct. IP was western blotted with anti-Flag to detect RIP1 interaction. (e) 293T cells expressing EDD and Flag-cIAP1, Flag-XIAP, or vector control. EDD
immunoprecipitated and western blotted with anti-Flag to detect IAP binding. (f) EDD immunoprecipitated from 293T cells expressing indicated Flag-cIAP1 construct and
western blotted with anti-Flag to detect interaction of cIAP1 construct. All experiments were repeated at least two times. * Indicates a non-speciﬁc band
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Cell Death and Disease(Supplementary Figure S2e). An inhibitor of NF-kB, SN50,
29
did not block zVAD.fmk-induced TNFa release in J774 cells
(Supplementary Figure S2f). Thus, we conclude that TNFa
production induced by zVAD.fmk or SM is independent of
NF-kB activity.
Lipopolysaccharide (LPS) is a pro-inﬂammatory stimulus
found on the outer membrane of bacteria that activates TNFa
transcription. Although LPS-induced TNFa is dependent on
NF-kB, we tested the role of RIP1 and EDD in this pathway of
TNFa production. Neither Nec-1 nor EDD knockdown was
Figure 6 RIP1 and EDD activate JNK signaling and TNFa production. (a) L929 cells treated with 20mM zVAD.fmk or 100nM SM-164 ±10mM Nec-1 for 2, 4, and 8h.
Cells lysates were western blotted to determine NF-kB activation (representative of two independent experiments). (b) WT J774 cells (top) or stable EDD knockdown cells
(bottom)treatedwith1mg/mlLPS±Nec-1for2handTNFalevelsmeasuredbyELISAinthecelllysate(NS).(c)ATPassayofL929cellstreatedasindicated±10mMNec-1
or 1mg/ml JNK inhibitor SP600125 for 24h. (d) J774 TNFa mRNA levels determined by RT-PCR after treatment with 20mM zVAD.fmk ±1mg/ml SP600125 for 2 and 4h.
Foldchangecalculatedby comparingwith GAPDHcontroland normalizingto untreated cells. (e) J774 cells(left) or J774EDD stable knockdowncell lines (right) were treated
with zVAD.fmk±Nec-1 as indicated for 15min, 30min, 1, 2, or 4h and western blotted with anti-phospho-JNK (pJNK) (representative of three independent experiments).
(f) ATP assay of L929 cells transfected with siRNA targetingSp1 for 48h and treatedwith 20mM zVAD.fmk, 100nM SM-164, or 10ng/ml hTNFa for 24h. Cell lysateswestern
blotted to conﬁrm knockdown of Sp1. *Po0.05, data shown are mean±S.E.M., for all experiments n¼3
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Cell Death and Diseaseable to block LPS-induced TNFa (Figure 6b). Thus, RIP1 and
EDD activation of TNFa production is distinct from NF-kB-
dependent pathways such as LPS-induced TNFa.
JNK signaling activates TNFa transcription downstream
of RIP1 and EDD. Our siRNA screen identiﬁed a number of
transcription factors as hits, including c-Jun and Sp1, both of
which can be activated by JNK and MAPK signaling.
11,30,31
The importance of c-Jun/AP-1 in mediating TNFa transcrip-
tion and cell death in response to zVAD.fmk has already
been conﬁrmed.
19,28 Inhibition of JNK signaling blocks
zVAD.fmk-, SM-, or Traf2 knockdown-induced necroptosis
(Figure 6c). The JNK inhibitor SP600125 blocks TNFa
transcription induced by zVAD.fmk (Figure 6d). Consistently,
increased phosphorylation of JNK, indicating JNK kinase
activation, was observed shortly after zVAD.fmk treatment.
A deﬁnitive role for RIP1 kinase in activating JNK signaling
has not been previously shown. We found that JNK phosphory-
lation after zVAD.fmk was attenuated in Nec-1-treated
and EDD-knockdown cells (Figure 6e, Supplementary
Figure S3a). SM stimulation also activates JNK signaling
in a manner dependent on RIP1 kinase and EDD
(Supplementary Figure S3b). Thus, RIP1 kinase and EDD
activate JNK signaling to induce TNFa transcription.
TNFa itself can also activate JNK. Nec-1, however, has no
effectonTNFa-inducedJNKphosphorylation(Supplementary
FigureS3c).AIP1/Dab2IP,anASK1(JNKMAP3K)interacting
protein, is reportedly a substrate of RIP1 after TNFa
stimulation.
32 However, neither knockdown of AIP1/Dab2IP
nor knockdown of ASK1 in our siRNA screen
11 protected
against zVAD.fmk-induced cell death (Supplementary
Figure S3d). TNFa-induced JNK activation is RIP1 kinase
independent and is activated by a separate pathway from
zVAD.fmk treatment.
Analysis of our siRNA screen showed a signiﬁcant
enrichment of screen hits with Sp1-binding sites in their
promoters, suggesting that Sp1 regulates transcription of
genes required for necroptosis.
11 Consistent with this
possibility, we found that knockdown of Sp1 speciﬁcally
inhibits zVAD.fmk- or SM-induced cell death but not TNFa-
induced necroptosis, similar to EDD knockdown (Figure 6f).
Sp1 is able to synergize with c-Jun/AP-1 to activate TNFa
transcription.
33 It is likely that both of these transcription
factors are activated by JNK signaling downstream of RIP1
kinase and EDD to promote transcription of TNFa and
possibly other genes in response to zVAD.fmk or SM
stimulation.
Discussion
RIP1 kinase has been previously shown to speciﬁcally
mediate TNFa-induced necroptosis downstream of TNFR1
by regulating the formation of complex IIb.
34,35 In this study,
we demonstrate a novel function of RIP1 kinase involving
its interaction with EDD to regulate JNK activation and TNFa
production. This pathway of TNFa production is activated
speciﬁcally in response to treatment with zVAD.fmk or SM, or
by knockdown of Traf2 and is distinguishable from the TNFa
production pathway regulated by NF-kB that can be activated
by TLR signaling (Figure 7). We show that activation of this
RIP1 kinase-dependent pathway leads to TNFa transcrip-
tional activation. Our examination of this pathway indicates
that RIP1 kinase and EDD mediate a common pathway of
JNK activation and TNFa production in mouse and human
systems, cell types such as macrophages and breast cancer
cells, and in cells capable of undergoing either apoptosis or
necroptosis. Our study suggests that RIP1 kinase not only
regulates necroptosis downstream of TNFR1 signaling,
but also has an important role in mediating the production
of TNFa.
The role of RIP1 kinase in activating TNFa production is
distinct from its role in mediating necroptosis. The function of
RIP1 in TNFa production may provide a possible explanation
for situations where Nec-1 was found to protect against
apoptosis. MDA-MB-231 cells treated with a low dose of SM
undergo typical TNFa-dependent apoptosis that can be
blocked by Nec-1. This is due Nec-1 inhibiting the production
of TNFa, which is required for apoptosis to occur after SM
treatment, rather than a role of RIP1 kinase in mediating
apoptosis itself. SM are currently in clinical trials as an anti-
cancer treatment, indicating the role of RIP1 kinase in
mediating the production of TNFa may be relevant for SM
activity in vivo.
Both cIAP1/2 and Traf2 have been implicated as E3
ubiquitin ligases targeting RIP1.
5,36 The ﬁnding that loss of
either cIAP1/2 or Traf2 can activate RIP1 suggests that these
proteins normally function to keep RIP1 inactive. traf2 / 
mice are normal at birth but become progressively runted and
dieprematurely withelevatedserum TNFalevels.
24The lethal
phenotypeisrescuedbythelossofTNFaorTNFR1indouble-
knockout traf2 /  tnf /  or traf2 /  tnfr1 /  mice.
37
Our study suggests the possibility that RIP1 kinase regulated
JNK activation mediates the production of TNFa in these
mouse models of human diseases. The identiﬁcation of SM
and Traf2 knockdown as inducers of RIP1 kinase-mediated
AP-1
cIAP1
Traf2
RIP1
EDD
zVAD
JNK
Sp1
TNFα mRNA TNFα
Inflammation
Apoptosis
Necroptosis
Nec-1
Figure 7 Model of RIP1- and EDD-mediated pathway of TNFa production.
RIP1 kinase-dependent TNFa production can be activated by the treatment with
zVAD.fmk, SM to degrade cIAP1/2, or by knockdown of Traf2. EDD, RIP1, and
cIAP1 are constitutively bound and RIP1 kinase and EDD activate JNK signaling
after stimulation. Traf2 and cIAP1 also constitutively interact. JNK activates the
transcription factors AP-1 and Sp1, which transcribe TNFa mRNA. Nec-1 inhibits
the activation of JNK and production of TNFa. TNFa produced can elicit
inﬂammatory responses and induce cell death in the surrounding cells
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be regulated directly by ubiquitination by cIAP1/2 and/or
Traf2.
SMs, in addition to inducing the degradation of cIAP1 and
cIAP2, and inhibit the activity of XIAP.
6,20 Many of the cellular
effects of SM in sensitizing cells to apoptosis have been
attributed to the loss of caspase inhibition by XIAP.
8,20
However, the effect of SM on RIP1 is likely due to the
degradation of cIAP1/2, as the effect of SM on TNFa
production was recapitulated in cIAP1-knockout cells but not
XIAP-deﬁcient cells.
10 Furthermore, EDD speciﬁcally inter-
acts with cIAP1, so it is likely that they act in the same
pathway.
EDDhasbeenimplicatedindiversecellularprocessessuch
as the DNA damage response and gene expression. EDD
constitutively binds RIP1 kinase and the E3 ubiquitin ligase
cIAP1. We propose thatEDD functionsas a scaffoldprotein in
this pathway and interacts with the critical regulatory proteins.
Similar to its role in mediating ATM phosphorylation of its
substrates p53 and CHK2,
15–17 EDD may also mediate RIP1
phosphorylation of its substrate(s) in this pathway. We
propose that EDD and RIP1 kinase mediate the activation of
JNK signaling, potentially via recruitment of a RIP1 substrate
thatactivatesJNK tomediate multiplesignaling pathwaysthat
are regulated by JNK. Future work is needed to determine
how RIP1 kinase and EDD activate the JNK signaling
pathway.
Materials and Methods
Gene knockdown experiments. L929 and MDA-MB-231 cells were
reverse transfected with 25-50nM siRNA (Dharmacon, Lafayette, CO, USA) in
384-well plates (Corning, Lowell, MA, USA) using HiPerfect transfection reagent
(Qiagen, Gaithersburg, MD, USA), according to the manufacturers protocol. After
48h of transfection, the cells were treated with zVAD.fmk, hTNFa, or SM-164.
After 18–24h, cell viability was determined by ATP assay using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Fitchburg, WI, USA). Stable
knockdown cell lines were generated using a retroviral or lentiviral expression
system to infect L929 or J774 cells, respectively. Expression of pSRP or pLKO.1
and packaging vectors were transfected into 293T cells to generate virus. L929 or
J774 cells were infected with the virus and selected in medium containing 10mg/ml
or 2mg/ml puromycin, respectively.
TNFa ELISA. J774 cells were plated 1 10
5cells/well in 24-well plates or
L929 cells plated 4 10
6cells/10-cm plate, treated, and the cell supernatant
collected or cells lysed in 1% Triton X-100 in PBS supplemented with Complete
Protease Inhibitor (Roche, Indianapolis, IN, USA). Total protein levels were
determined by Bradford protein assay (Bio-rad, Hercules, CA, USA). The levels of
TNFa in cell lysate or supernatant were quantiﬁed using the mTNFa ELISA
kit according to the manufacturers instructions (R&D Systems, Minneapolis,
MN, USA).
Real-time PCR. To determine mRNA levels of TNFa in the cell, RNA was
harvested according to the manufacturers protocol using the Qiagen RNeasy kit.
One microgram of RNA was reverse transcribed with random hexamers and
SuperScript II First Strand cDNA Synthesis System (Invitrogen, Carlsbad, CA,
USA). The qPCR performed using 2  SYBR green master mix on the ABI
7900HT qPCR machine (Applied Biosystems, Carlsbad, CA, USA). Fold change in
RNA was calculated using the comparative Ct method, normalizing to 18S rRNA
or GAPDH control. Taqman probes were used for mTNFa and GAPDH (Applied
Biosystems). Primers used are as follows: mTNFa (forward: 50-CTTCTCAT
TCCTGCTTGTGG-30, reverse: 50-ATGAGAGGGAGGCCATTTG-30), hTNFa
(forward: 50-GAGGCCAAGCCCTGGTATG-30, reverse: 50-CGGGCCGATTGATCT
CAGC-30 PrimerBank ID 25952110b2),
38 or 18S rRNA (foward: 50-CCTGCGGCTT
AATTTGACTC-30, reverse: 50-AGACAAATCGCTCCACCAAC-30).
Coimmunoprecipitation. 293T cells were transfected by the calcium
phosphate method and lysed after 24h in 50mM Tris-Cl pH 7.5, 150mM NaCl,
1m M EDTA, 1% NP-40, 10% glycerol, and protease inhibitor cocktail (Roche).
L929 cells were lysed in the buffer described except with 50mM NaCl and 0.5%
NP-40. The indicated antibody was used with protein A/G sepharose beads
(Thermo Scientiﬁc, Waltham, MA, USA) for immunoprecipitation. IP was analyzed
by SDS-PAGE and western blot.
Mass spectrometry of RIP1 interacting proteins. 293T cells were
transfected by the calcium phosphate method with Flag-tagged RIP1 for 48h.
The cells were lysed (20mM HEPES (pH 7.3), 5mM EDTA, 150mM NaCl, 5mM
NaF, 0.2mM NaVO3, 1% Triton X-100, complete protease inhibitor cocktail) and
immunoprecipitated using anti-Flag M2 agarose (Sigma, St. Louis, MO, USA). The
beads were washed 5  with lysis buffer and the bound proteins eluted using
150ng/ml Flag peptide. The eluted proteins were TCA precipitated and identiﬁed
by mass spectrometry.
Expression vectors. The following plasmids were used: pcDNA3-Flag-RIP1
WT, DKD, DC, and DDD. RIP1 DKD was constructed using the following primers:
50-CGAATCCGGAATTCCGGCCGACATTT-30, and 50-TGCAGACTCGAGGTTC
TGGCTGACGTAAAT-30 to PCR a fragment from nt 843-2007 (NM_003804).
RIP1 DDD was constructed using the forward primer 50-ACGATGACGATAAAG
AATTCAGGATGCAA-30, and the reverse primer 50-AGGTGCTCGAGCGTCAG
ACTAGTGGTATT-30 to PCR a fragment from nt 1-1751 (NM_003804). RIP1 DC
was constructed using the same forward primer as the DDD construct and the
reverse primer 50-TTCTTCTAATTGCTCGAGATAAAAAGGCCT-30 to PCR a
fragment from nt 1-885 (NM_003804). Each of the PCR fragments was cloned
into pcDNA3 using EcoRI and XhoI. pCMV-Tag2b-Flag-EDD (courtesy of C.K.W.
Watts); Flag-XIAP; Flag-cIAP1, WT and the truncation constructs BIR1-2, BIR1-3,
BIR3-RING, CARD-RING, RING. The shRNAs targeting EDD were inserted into
the empty vector backbone (sequences: 50-TGACAGCAGAACAACATAATT-30 in
pSRP; 50-GCTCGTCTTGATCTACTTTAT-30 in pLKO.1) (courtesy of K.P. Lu).
Antibodies and reagents. The primary antibodies used were anti-RIP1 (BD
Biosciences, San Jose, CA, USA), anti-EDD (Novus Biologicals for IP, rat monoclonal
raised against aa 459–794 for WB), anti-pJNK, anti-JNK, and anti-NF-kB2 (Cell
Signaling), anti-NF-kB1, anti-IkBa, and anti-Traf2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-cIAP1, anti-Flag M2 (Sigma), and anti-mouse and anti-human
TNFa-neutralizing antibodies (R&D Systems). The compounds used were zVAD.fmk,
hTNFa (Cell Sciences, Canton, MA, USA), SM-164 (kindly provided by Dr. Xiaomeng
Wang),
20,21 7-Cl-O-Nec-1,
3 SP600125 (A.G. Scientiﬁc, San Diego, CA, USA),
SN50/SN50M (Calbiochem, Darmstadt, Germany), and LPS (Sigma).
Tissue culture. L929, J774, and 293T cells were maintained in DMEM
supplemented with 10% FBS and penicillin and streptomycin (Invitrogen). MDA-
MB-231 cells were grown in RPMI with 10% FBS, penicillin, and streptomycin
(Invitrogen).
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